Challenges in IBD Research: Precision Medicine.
暂无分享,去创建一个
Judy H Cho | Mark Curran | Judy H. Cho | Lee A Denson | Dermot P B McGovern | Walter A Koltun | Richard H Duerr | Sandra C Kim | R Balfour Sartor | Francisco A Sylvester | Clara Abraham | Edwin F de Zoeten | Corey A Siegel | Richéal M Burns | Angela M Dobes | Nataly Shtraizent | Gerard Honig | Caren A Heller | Andrés Hurtado-Lorenzo | R. Duerr | C. Abraham | W. Koltun | D. McGovern | R. Sartor | C. Siegel | M. Curran | L. Denson | F. Sylvester | Sandra C. Kim | E. D. de Zoeten | R. Burns | N. Shtraizent | Gerard Honig | A. Hurtado-Lorenzo | C. Heller | A. Dobes | Judy H. Cho
[1] R. Owens,et al. Oncostatin M drives intestinal inflammation in mice and its abundance predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease , 2017, Nature Medicine.
[2] J. Faith,et al. Challenges in IBD Research: Preclinical Human IBD Mechanisms. , 2019, Inflammatory bowel diseases.
[3] J. Satsangi,et al. Biomarkers in Search of Precision Medicine in IBD , 2016, The American Journal of Gastroenterology.
[4] Samir A. Shah,et al. Serum Proteome Profiles in Stricturing Crohn's Disease: A Pilot Study , 2015, Inflammatory bowel diseases.
[5] L. Peyrin-Biroulet,et al. Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases. , 2017, Gastroenterology.
[6] Manolis Kellis,et al. Challenges in IBD Research: Environmental Triggers. , 2019, Inflammatory bowel diseases.
[7] H. Uhlig,et al. Clinical Genomics in Inflammatory Bowel Disease. , 2017, Trends in genetics : TIG.
[8] G Van Assche,et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis , 2009, Gut.
[9] Timothy L. Tickle,et al. Pediatric Crohn disease patients exhibit specific ileal transcriptome and microbiome signature. , 2014, The Journal of clinical investigation.
[10] D. Iliopoulos,et al. The IBD interactome: an integrated view of aetiology, pathogenesis and therapy , 2017, Nature Reviews Gastroenterology & Hepatology.
[11] Andrea Califano,et al. Predicting Drug Response in Human Prostate Cancer from Preclinical Analysis of In Vivo Mouse Models. , 2015, Cell reports.
[12] D. Greco,et al. Targeted Analysis of Serum Proteins Encoded at Known Inflammatory Bowel Disease Risk Loci , 2018, Inflammatory bowel diseases.
[13] Frank I. Scott,et al. Challenges in IBD Research: Pragmatic Clinical Research. , 2019, Inflammatory bowel diseases.
[14] M. Cvancarova,et al. Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study) , 2015, Scandinavian journal of gastroenterology.
[15] Mary E. Haas,et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations , 2018, Nature Genetics.
[16] M. Dubinsky,et al. Real‐time tool to display the predicted disease course and treatment response for children with Crohn's disease , 2011, Inflammatory bowel diseases.
[17] Stanley B. Cohen,et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-α vs an immunomodulator in children with Crohn's disease. , 2014, Gastroenterology.
[18] Judy H. Cho,et al. Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study , 2017, The Lancet.
[19] U. Vogel,et al. Systematic review: genetic biomarkers associated with anti‐TNF treatment response in inflammatory bowel diseases , 2016, Alimentary pharmacology & therapeutics.
[20] James M. Dahlhamer,et al. Prevalence of Inflammatory Bowel Disease Among Adults Aged ≥18 Years - United States, 2015. , 2016, MMWR. Morbidity and mortality weekly report.
[21] M. Vatn,et al. Risk Matrix for Prediction of Advanced Disease in a Population-based Study of Patients with Crohn's Disease (the IBSEN Study) , 2014, Inflammatory bowel diseases.
[22] T. Lu,et al. Challenges in IBD Research: Novel Technologies. , 2019, Inflammatory bowel diseases.
[23] P. Rutgeerts,et al. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[24] Miles Parkes,et al. Gene expression profiling of CD8+ T cells predicts prognosis in patients with Crohn disease and ulcerative colitis. , 2011, The Journal of clinical investigation.
[25] B. Psaty,et al. Genetic predictors of medically refractory ulcerative colitis , 2010, Inflammatory bowel diseases.
[26] M. Bechtold,et al. pANCA Positivity Predicts Lower Clinical Response to Infliximab Therapy among Patients with IBD , 2015, Southern medical journal.
[27] Kristel Van Steen,et al. Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease‡ , 2010, Inflammatory bowel diseases.
[28] A. Griffiths,et al. Factors associated with early outcomes following standardized therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study , 2017, The lancet. Gastroenterology & hepatology.
[29] S. Targan,et al. Molecular Patterns in Human Ulcerative Colitis and Correlation with Response to Infliximab , 2014, Inflammatory bowel diseases.
[30] C. Klein,et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. , 2014, Gastroenterology.
[31] E. Loftus,et al. Incidence and Prevalence of Crohn’s Disease and Ulcerative Colitis in Olmsted County, Minnesota From 1970 Through 2010 , 2017, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[32] B. Ye,et al. Development of a Novel Predictive Model for the Clinical Course of Crohn's Disease: Results from the CONNECT Study , 2017, Inflammatory bowel diseases.